Microvascular disease and its role in the brain and cardiovascular system: A potential role for uric acid as a cardiorenal toxin

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 430-437

  Kanbay, Mehmet ^a   Snchez Lozada, Laura Gabriela ^b   Franco, Martha ^b   Madero, Magdalena ^b   Solak, Yalcin ^c   Rodriguez Iturbe, Bernardo ^d   Covic, Adrian ^e   Johnson, Richard J ^f  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b INC Ignacio Chavez ^*  (Mexico)

^c SELCUK UNIVERSITY   (Turkey)

^d HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^e GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

arteriolosclerosis; autoregulation; chronic kidney disease; fructose; uric acid

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOPURINOL; ALPHA TOCOPHEROL; ARGININE; BETA CAROTENE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; FRUCTOSE; FRUCTOSE 1 PHOSPHATE; INOSINE PHOSPHATE; OXONIC ACID; URIC ACID; VITAMIN D;

APOPTOSIS; ARTERIOLE; ARTERIOLOSCLEROSIS; ARTERIOSCLEROSIS; ARTERY DISEASE; AUTOREGULATION; CARDIOVASCULAR SYSTEM; CELL INFILTRATION; CELL PROLIFERATION; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; HYPERTENSION; HYPERURICEMIA; MULTIINFARCT DEMENTIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; STROKE; SUGAR INTAKE; TREATMENT OUTCOME; VASOCONSTRICTION; VITAMIN D METABOLISM;

ARTERIOSCLEROSIS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; MICROVESSELS; MYOCARDIAL INFARCTION; STROKE;

EID: 79551497664     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq635     Document Type: Review

References (83)

1. Gull WW, Sutton HG. On the pathology of the morbid state commonly called chronic Bright's disease with contracted kidney (arterio- capillary fibrosis). Med Chir Trans 1872; 55: 325-371
2. Johnson G. The anatomy of Bright's disease: the arterio-capillary fibrosis of Sir William Gull and Dr. Sutton. BMJ 1872; I: 604-605
3. Moritz AR, Oldt MR. Arteriolar sclerosis in hypertensive and nonhypertensive individuals. Am J Pathol 1937; 13: 679-728
4. Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955; 1: 33-42
5. Walker MB, Boyd GW. The distribution of arteriolosclerosis along the arterioles in DOCA hypertensive rats. Clin Exp Pharmacol Physiol 1983; 10: 319-323
6. Sumpio BE, Widmann MD, Ricotta J et al. Increased ambient pressure stimulates proliferation and morphologic changes in cultured endothelial cells. J Cell Physiol 1994; 158: 133-139
7. Hishikawa K, Nakaki T, Marumo T et al. Pressure promotes DNA synthesis in rat cultured vascular smooth muscle cells. J Clin Invest 1994; 93: 1975-1980
8. Lombardi D, Gordon KL, Polinsky P et al. Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension 1999; 33: 1013-1019
9. Wiener J, Lombardi DM, Su JE et al. Immunohistochemical and molecular characterization of the differential response of the rat mesenteric microvasculature to angiotensin-II infusion. J Vasc Res 1996; 33: 195-208
10. Chatziantoniou C, Ardaillou R, Boffa JJ et al. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest 1998; 101: 2780-2789
11. Quiroz Y, Pons H, Gordon KL et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 2001; 281: F38-F47
12. Andoh TF, Johnson RJ, Lam T et al. Subclinical renal injury induced by transient cyclosporine exposure is associated with salt-sensitive hypertension. Am J Transplant 2001; 1: 222-227
13. Sanchez-Lozada LG, Tapia E, Jimenez A et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol 2007; 292: F423-F429
14. Sanchez-Lozada LG, Tapia E, Johnson RJ et al. Glomerular hemodynamic changes associated with arteriolar lesions and tubulointerstitial inflammation. Kidney Int Suppl 2003; 86: S9-S14
15. Ames BN, Cathcart R, Schwiers E et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-6862
16. Nieto FJ, Iribarren C, Gross MD et al. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-139
17. Reyes AJ, Leary WP. The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid? Cardiovasc Drugs Ther 2002; 16: 485-487
18. Corry DB, Eslami P, Yamamoto K et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008; 26: 269-275
19. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293
20. Kang DH, Park SK, Lee IK et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562
21. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8608
22. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742
23. Zharikov S, Krotova K, Hu H et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008; 295: C1183-C1190
24. Sanchez-Lozada LG, Tapia E, Santamaria J et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247
25. Mazzali M, Kim YG, Suga S et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001; 71: 900-905
26. Hsu CH, Patel SR, Young EW et al. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 1991; 260: F596-F601
27. Vanholder R, Patel S, Hsu CH. Effect of uric acid on plasma levels of 1, 25(OH)2D in renal failure. J Am Soc Nephrol 1993; 4: 1035-1038
28. Su EJ, Lombardi DM, Siegal J et al. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998; 31: 1331-1337
29. Mazzali M, Kanellis J, Han L et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997
30. Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension 2004; 43: 752-759
31. Goldblatt H, Lynch J, Hanzal RFet al. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59: 347-379
32. Mattson DL, James L, Berdan EA et al. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2006; 48: 149-156
33. Pechman KR, Basile DP, Lund H et al. Immune suppression blocks sodium-sensitive hypertension following recovery from ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1234-R1239
34. Pechman KR, De Miguel C, Lund H et al. Recovery from renal ischemia-reperfusion injury is associated with altered renal hemodynamics, blunted pressure natriuresis, and sodium-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1358-R1363
35. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J et al. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 2004; 286: F606-F616
36. Stewart T, Jung FF, Manning J et al. Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension. Kidney Int 2005; 68: 2180-2188
37. Tian N, Gu JW, Jordan S et al. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol 2007; 292: H1018-H1025
38. Sanchez-Lozada LG, Soto V, Tapia E et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008; 295: F1134-F1141
39. Sanchez-Lozada LG, Tapia E, Lopez-Molina R et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol 2007; 292: F1238-F1244
40. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360
41. Johnson RJ, Herrera-Acosta J, Schreiner GF et al. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-923
42. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821
43. Choi JW, Ford ES, Gao X et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109-116
44. Jalal DSG, Johnson RJ et al. Increased fructose intake from added sugars is independently associated with elevated blood pressure. Findings from the National Health and Nutrition Examination Survey (2003-2006). J Am Soc Nephrol 2009; 20: 9A-10A
45. Perez-Pozo SE, Schold J, Nakagawa T et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes (Lond) 2010; 34: 454-461
46. Perlstein TS, Gumieniak O, Williams GH et al. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006; 48: 1031-1036
47. Sundstrom J, Sullivan L, D'Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33
48. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924-932
49. Kanbay M, Ozkara A, Selcoki Y et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-1233
50. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59
51. Hallfrisch J. Metabolic effects of dietary fructose. FASEB J 1990; 4: 2652-2660
52. Smith CM, Rovamo LM, Raivio KO. Fructose-induced adenine nucleotide catabolism in isolated rat hepatocytes. Can J Biochem 1977; 55: 1237-1240
53. Choi JW, Ford ES, Gao X et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 59: 109-116
54. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44: 595-601
55. Thompson CS, Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke 2009; 40: e322-e330
56. Bidani AK, Griffin KA. Long-term renal consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens 2002; 11: 73-80
57. Fogo A, Breyer JA, Smith MC et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51: 244-252
58. Hill GS, Heudes D, Bariety J. Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 2003; 63: 1027-1036
59. Hill GS, Heudes D, Jacquot C et al. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006; 69: 823-831
60. Manolio TA, Olson J, Longstreth WT. Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep 2003; 5: 255-261
61. Simon G. Why do treated hypertensives suffer strokes? An internist's perspective. J Clin Hypertens (Greenwich) 2002; 4: 338-344
62. Schiller A, Covic A. Kidney and brain-a renal perspective of 'Les Liaisons Dangereuses'. Nephrol Dial Transplant 2010; 25: 1370-1373
63. Schretlen DJ, Inscore AB, Jinnah HA et al. Serum uric acid and cognitive function in community-dwelling older adults. Neuropsychology 2007; 21: 136-140
64. Schretlen DJ, Inscore AB, Vannorsdall TD et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423
65. Stephan BC, Wells JC, Brayne C et al. Increased fructose intake as a risk factor for dementia. J Gerontol A Biol Sci Med Sci 2010; 65: 809-814
66. Euser SM, Hofman A, Westendorp RG et al. Serum uric acid and cognitive function and dementia. Brain 2009; 132: 377-382
67. Kim SY, Guevara JP, Kim KM et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 885-892
68. Holme I, Aastveit AH, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009; 266: 558-570
69. Khatri M, Wright CB, Nickolas TL et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 2007; 38: 3121-3126
70. Cho AH, Lee SB, Han SJ et al. Impaired kidney function and cerebral microbleeds in patients with acute ischemic stroke. Neurology 2009; 73: 1645-1648
71. Kobayashi S, Ikeda T, Moriya H et al. Asymptomatic cerebral lacunae in patients with chronic kidney disease. Am J Kidney Dis 2004; 44: 35-41
72. King SB 3rd, Smith SC Jr., Hirshfeld JW Jr. et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update For Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51: 172-209
73. Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299: 1036-1045
74. Boffa JJ, Lu Y, Placier S et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14: 1132-1144
75. Ying L, Flamant M, Vandermeersch S et al. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. Hypertension 2003; 42: 937-944
76. Schiffrin EL. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor. J Cardiovasc Pharmacol 1996; 27: S13-S18
77. Schiffrin EL. Vascular remodeling and endothelial function in hypertensive patients: effects of antihypertensive therapy. Scand Cardiovasc J Suppl 1998; 47: 15-21
78. Smith RD, Yokoyama H, Averill DB et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (the VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006; 6: 335-342
79. Placier S, Boffa JJ, Dussaule JC et al. Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant 2006; 21: 881-888
80. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393
81. Noman A, Ang DS, Ogston S et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-2167
82. Ogino K, Kato M, Furuse Y et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebocontrolled crossover preliminary study. Circ Heart Fail 2010; 3: 73-81
83. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300: 922-930